DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort

Direct-acting antiviral (DAA) HCV therapy is used in decompensated cirrhosis with the expectation of improvement in hepatic function. Little is known about the long-term benefit of successful treatment.

Source: Journal of Hepatology - March 30, 2020 Category: Gastroenterology Authors: Elizabeth C. Verna, Giuseppe Morelli, Norah A. Terrault, Anna S. Lok, Joseph K. Lim, Adrian M. Di Bisceglie, Stefan Zeuzem, Charles S. Landis, Paul Kwo, Mohamed Hassan, Michael P. Manns, Monika Vainorius, Lucy Akushevich, David R. Nelson, Michael W. Fried Source Type: research